Aryl Hydrocarbon Receptor Global Market Report 2025

The aryl hydrocarbon receptor market size has grown strongly in recent years. It will grow from $4.64 billion in 2024 to $5.01 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period can be attributed to factors such as increased awareness of environmental toxins, expanded research in oncology, a surge in autoimmune disease studies, greater interest in targeted therapies, and the growing use of these therapies in drug development.

The aryl hydrocarbon receptor market size is expected to see strong growth in the next few years. It will grow to $6.79 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth during the forecast period can be attributed to increased investment in precision medicine, rising demand for immunotherapy, a stronger focus on environmental health, expanding applications for inflammatory diseases, and continued advancements in drug discovery. Key trends in this period include progress in targeted cancer therapies, widespread adoption of precision medicine approaches, advancements in toxicology research, the integration of AI in drug discovery, and improvements in autoimmune disease treatments.

The increase in autoimmune diseases and chronic conditions is expected to drive the growth of the aryl hydrocarbon receptor (AHR) market in the coming years. Autoimmune diseases and chronic conditions are long-lasting disorders where the immune system malfunctions or health issues persist. The rise in these conditions is linked to factors such as genetics, environmental influences, lifestyle changes, gut imbalances, and improved diagnostic capabilities. AHR agonists have the potential to regulate immune responses and inflammation, offering therapeutic benefits for autoimmune diseases and chronic conditions by influencing T-cell differentiation and immune cell function. For example, in July 2023, Public Health Scotland reported that newly diagnosed cases of multiple sclerosis (MS) in 2022 increased by 87.2%, compared to 85.7% the previous year, with 491 new cases recorded, bringing the total to 6,359. As a result, the rise in autoimmune diseases and chronic conditions is propelling the growth of the AHR agonist market.

Companies in the AHR market are focusing on developing advanced treatments, such as topical medications that target specific inflammatory pathways. These treatments offer potential solutions for autoimmune diseases such as psoriasis, multiple sclerosis, and other chronic inflammatory conditions while minimizing systemic side effects. Topical medications are applied directly to the skin or mucous membranes to treat localized conditions or symptoms. For example, in May 2022, Dermavant Sciences, a US-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for VTAMA (tapinarof) cream, 1%. This non-steroidal treatment option provides a unique mechanism of action through selective AHR modulation. Designed for once-daily application, VTAMA has shown a favorable safety profile with minimal systemic absorption, setting it apart from traditional therapies.

In September 2024, Organon & Co., a US-based pharmaceutical company, acquired Dermavant Sciences Ltd. for approximately $1.2 billion. This acquisition allows Organon to strengthen its dermatology portfolio by incorporating Dermavant's innovative dermatologic therapy, VTAMA (tapinarof) cream, 1%. Dermavant Sciences Ltd. specializes in developing AHR agonist-based therapies for dermatological conditions.

Major players in the aryl hydrocarbon receptor market are Bayer AG, Eli Lilly and Company, Organon & Co., Sigma-Aldrich Corporation, Bio-Techne Corporation, Abcam plc, R&D Systems Inc., Dermavant Sciences Inc., Cayman Chemical Company, Enzo Life Sciences Inc., Tocris Bioscience, Ikena Oncology Inc., MedChemExpress LLC, Hercules Pharmaceuticals BV, Active Biotech AB, AnTolRx Inc., Aqilion AB, Azora Therapeutics Australia Pty Ltd, Sol-Gel Technologies Ltd., and Actavalon Inc.

North America was the largest region in the aryl hydrocarbon receptor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in aryl hydrocarbon receptor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the aryl hydrocarbon receptor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The aryl hydrocarbon receptor is a protein that binds to environmental pollutants, such as dioxins, and regulates gene expression related to immune and inflammatory responses. It is used to modulate various biological processes, including the treatment of autoimmune and inflammatory conditions such as psoriasis, by selectively activating or inhibiting the receptor.

Key types of aryl hydrocarbon receptors include CB-993113, CDR-914K058, cinnabarinic acid, and others. CB-993113 is a small molecule inhibitor that targets the CBP/p300 bromodomain and is being studied for its potential to treat cancer and other diseases by modulating gene expression. These receptors and related compounds are distributed through various channels, such as direct sales, online platforms, distributors, retail pharmacies, and wholesale suppliers. They are used in treating conditions such as hepatocellular carcinoma, multiple sclerosis, obesity, and osteoporosis, and are applied across industries such as pharmaceuticals, biotechnology, agriculture, environmental consultancy, and research institutions.

The aryl hydrocarbon receptor market research report is one of a series of new reports that provides aryl hydrocarbon receptor market statistics, including the aryl hydrocarbon receptor industry global market size, regional shares, competitors with the aryl hydrocarbon receptor market share, detailed aryl hydrocarbon receptor market segments, market trends, and opportunities, and any further data you may need to thrive in the aryl hydrocarbon receptor industry. This aryl hydrocarbon receptor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The aryl hydrocarbon receptor market consists of sales of synthetic AHR agonists, natural AHR agonists, AHR-targeted enzyme inhibitors, and pharmaceuticals targeting AHR pathways. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.